Healing The World: Mir Imran- The Self Made Entrepreneur

By siliconindia   |   Monday, 15 June 2015, 12:56 Hrs
cmt right
Comment Right
cmt right
cmt right
Printer Print Email Email

BENGALURU: Mir Imran is in no way like the business visionaries of today. He's 59 years old, Mir does not hold a prestigious degree from a high ranking institute nor is he an engineer capable of producing software programmes. But he is a savior who is saving lives and curing the deadliest diseases with his own biomedical innovative products, reports The Economic Times.

For the last two and half decades he has opened numerous companies in association with his applied research lab ‘InCube’ in San Jose, which is the capital of Silicon Valley.

He holds over 400 U.S. exclusive rights and thousands of international copyrights, and has sold about 15 medical technology companies in his career. "I'm always hunting for big problems to solve," said Imran, who studied at All Saints High School in Hyderabad before he settled in New Jersey.

Imran was in the limelight for having hit upon the heavenly chalice of medication conveyance: a pill which can conceivably take out the requirement for excruciating infusions.

Rani Therapeutics, a name kept after his mother has constructed a component to convey a medication orally—rather than every day excruciating infusions for diseases including diabetes and different sclerosis. The organization, which raised about $25 million (Rs 160 crore) in a round drove by Google Ventures and Novartis, has tied up to test their scope of medications on its pill.

According to Mir Imran, "We can embed any biologic drug on our platform, for me, trained as an engineer, where most things have clear explanations and are deterministic, this was a big frustration when I was at medical school," reports ET.

Imran’s current research interests include tissue engineering, gastroenterology, nephrology, neurology, orthopedics, congestive heart failure and artificial organs. All fund invests in both InCube Labs’ companies as well as external companies. The fund primarily invests in novel therapies that have the potential to dramatically improve patient care.

Read More: 5 Businesses You Can Start Today With Less Than 50, 000 and Five Reasons Why There Won't Be A 'Made In India' iPhone In Near Future

SpiceJet plans aggressive
Budget passenger carrier SpiceJet plans to aggressively expand its international networks to fl..
GST rate cut to spur Bengaluru
The realty market in India's tech hub is set to grow as lower Goods and Services Tax (GST) rate..
Ola raises Rs 400 cr for electric
Leading ride-hailing cab aggregator Ola on Friday said it raised Rs 400 crore from its early in..
Fossil Group sells smartwatch
Global watch and accessories maker Fossil Group has announced to sell its smartphone technolog..